Scientists hunt for clues in rare cancer shrinkage
NCT ID NCT03728842
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study collects blood samples from 19 people whose metastatic melanoma or kidney cancer shrank without treatment. Researchers want to study the immune system's role in this rare event. The goal is to better understand what causes spontaneous regression, which could lead to new therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help scientists understand why some cancers regress spontaneously, potentially pointing toward new immune-based treatments.
- What could go wrong
- This is a very small, observational study with only 19 participants. It is not testing a treatment, so there is no direct benefit to patients, and findings may not apply to others.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA; RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Simon Cancer Center
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma